儿童血栓性血小板减少性紫癜

Melanie STEELE; Howard H.W. CHEN (陳浩偉); Jeremy STEELE; Anthony K.C. CHAN (陳錦泉); Keith K. LAU (劉廣洪)

PDF(920 KB)

中国当代儿科杂志 ›› 2012, Vol. 14 ›› Issue (11) : 803-810.

国外儿科研究

儿童血栓性血小板减少性紫癜

Melanie STEELE, Howard H.W. CHEN (陳浩偉), Jeremy STEELE, Anthony K.C. CHAN (陳錦泉), Keith K. LAU (劉廣洪)

作者信息 +

Thrombotic thrombocytopenic purpura in pediatric patients

Melanie STEELE, Howard H.W. CHEN, Jeremy STEELE, Anthony K.C. CHAN, Keith K. LAU

Author information +

文章历史 +

摘要

血栓性血小板减少性紫癜（TTP）在儿童病例中甚为少见，但如未能及时诊断及施予治疗，其后果则极为严重。其最常见之5种病症为：血小板减少、微血管溶血性贫血、急性肾衰竭、发热及中枢神经系统症状。但临床病例中，并不一定会同时出现上述5种症状。故此医疗人员对此病必须有极高之警觉性。TTP之病理特征包括：外周血涂片可见裂体细胞，Coombs 试验阴性，血清乳酸脱氢酶增高及中度或重度血小板减少。TTP发病机理主因缺乏ADAMTS13，从而引发微血管溶血性贫血及血小板减少。TTP可概括分为家族性TTP（Upshaw Schulman 综合征）和继发性TTP。家族性TTP是由于先天性ADAMTS13缺乏所致，其急性治疗法为血浆置换，当病情稳定后，可输注新鲜冰冻血浆以防止病情复发。继发性TTP是指患者因体内产生抗体而导致ADAMTS13功能减退，主要治疗方法亦为血浆置换，最新之临床文献显示rituxiamb对此症亦颇有治疗价值。

Abstract

Although thrombotic thrombocytopenic purpura (TTP) is rarely seen in pediatric patients, failure to recognize this condition often leads to severe consequences and poor outcomes. Classic features of TTP include thrombocytopenia, microangiopathic hemolytic anemia, acute kidney injury, fever, and central nervous system involvement. However, patients suffering from this condition may not present with all of the symptoms simultaneously. Therefore, it is of utmost importance for healthcare providers to have a high index of suspicion. Laboratory investigations may reveal the presence of schistocytes on peripheral blood smear, negative Coombs test, high lactate dehydrogenase levels and severely low platelet counts. The etiology of TTP is mainly due to insufficient cleavage of the large multimers of von Willebrand factor (vWF) secondary to decreased activity of ADAMTS13 (a disintegrin and metalloprotease with Thrombospondin type 1 repeats, member 13). TTP can be broadly classified into familial TTP (Upshaw Schulman syndrome) and non-familial TTP. Familial TTP is due to a congenital deficiency of ADAMTS13. Its mainstay of therapy is initiation of plasmapheresis during the acute phase, followed by regular fresh frozen plasma (FFP) infusions. Alternatively, non-familial TTP is due to a decrease in ADAMTS13 activity secondary to the presence of anti-ADAMTS13 antibodies. Once again, the primary treatment is plasmapheresis; however, recent anecdotal data also supports the use of rituximab in select cases.

导出引用

Melanie STEELE, Howard H.W. CHEN (陳浩偉), Jeremy STEELE, Anthony K.C. CHAN (陳錦泉), Keith K. LAU (劉廣洪). 儿童血栓性血小板减少性紫癜[J]. 中国当代儿科杂志. 2012, 14(11): 803-810

Melanie STEELE, Howard H.W. CHEN, Jeremy STEELE, Anthony K.C. CHAN, Keith K. LAU. Thrombotic thrombocytopenic purpura in pediatric patients[J]. Chinese Journal of Contemporary Pediatrics. 2012, 14(11): 803-810

中图分类号： R722

参考文献

［1］Yagi H, Matsumoto M, Fujimura Y. Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency［J］. Presse Med, 2012,41(3 Pt 2): e137-e155.

［2］Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group［J］. N Engl J Med, 1991, 325(6): 393-397.

［3］Tsai HM. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura［J］. Kidney Int Suppl, 2009, 112: S11-S14.

［4］Bouw MC, Dors N, van Ommen H, Ramakers-van Woerden NL. Thrombotic thrombocytopenic purpura in childhood［J］. Pediatr Blood Cancer, 2009, 53(4): 537-542.

［5］Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature［J］. Medicine, 1966, 45: 139-159.

［6］Kessler CS, Khan BA, Lai-Miller K. Thrombotic thrombocytopenic purpura: a hematological emergency［J］. J Emerg Med, 2012 Mar 23. ［Epub ahead of print］.

［7］Davis A, Barnes C. Thrombotic thrombocytopenic purpura in childhood: an uncommon but life-threatening cause of thrombocytopenia［J］. J Paediatr Child Heath, 2007, 43(9): 640-642.

［8］George JN, Kremer Hovinga JA, Terrel DR, Vesely SK, L-mmle B. The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry: the Swiss connection［J］. Eur J Haematol, 2008, 80(4): 277-286.

［9］Clark WF. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange［J］. Semin Dial, 2012, 25(2):214-219.

［10］Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura［J］. Nature, 2001, 413(6855): 488-494.

［11］Furlan M, Robles R, Galbusera M, Kyrle PA, Brenner B, Krause M, et al. Von Willebrand factor cleaving protease in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome［J］. N Engl J Med, 1998, 339(22): 1578-1584.

［12］Prestridge TD, Rurali E, Wadsworth L, Wu JK, Moore JC, Bresin E. Congenital thrombotic thrombocytopenic purpura (cTTP) with two novel mutations［J］. Pediatr Blood Cancer, 2012 Apr 5. doi: 10.1002/pbc.24159. ［Epub ahead of print］.

［13］Loirat C, Girma JP, Desconclois C, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children［J］. Pediatr Nephrol, 2009, 24(1): 19-29.

［14］Klukowska A, Niewiadomska E, Budde U, Oyen F, Schneppenheim R. Difficulties in diagnosing congenital thrombotic thrombocytopenic purpura［J］. J Pediatr Hematol Oncol, 2010, 32(2): 103-107.

［15］Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura［J］. J Thromb Haemost, 2010, 8(4): 631-640.

［16］Schmugge M, Dunn MS, Amankwah KS, Blanchette VS, Freedman J, Rand ML. The activity of the von Willebrand factor cleaving protease ADAMTS-13 in newborn infants［J］. J Thromb Haemost, 2004, 2(2): 228-233.

［17］Daghistani D, Jimenez JJ, Moake JL, Ledford MR, yunis AA. Familial infantile thrombotic thrombocytopenic purpura［J］. J Pediatr Hematol Oncol, 1996, 18(2): 171-174.

［18］Born H, Peters A, Ettinger R. Inherited ADAMTS13 deficiency: Unique presentation and treatment［J］. Pediatr Blood Cancer, 2008, 50(5): 956-957.

［19］Scully M, Gattens M, Khair K, Liesner R. The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura［J］. Br J Haematol, 2006, 135(1): 101-104.

［20］Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, Kn-bl P, Jilma B. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura［J］. J Thromb Haemost, 2011, 106(3): 539-547.

［21］Park HW, Oh D, Kim N, Cho HY, Moon KC, Chae JH, et al. Congenital thrombotic thrombocytopenic purpura associated with unilateral moyamoya disease［J］. Pediatr Nephrol, 2008; 23(9): 1555-1558.

［22］Jain P, Yoganathan S, Sharma S, Motwani J, Kumar A, Kabra M, et al. Congenital thrombotic thrombocytopenic purpura associated with moyamoya syndrome in a 3-year-old girl: A case report［J］. J Child Neurol, 2012 Feb 28. ［Epub ahead of print］.

［23］Terrell DR, Williams LA, Vesely SK, L-mmle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: All patients, idiopathic patients, and patients with severe ADAMTS13 deficiency［J］. J Thromb Haemost, 2005, 3(7): 1432-1436.

［24］Schneppenheim R, Budde U, Hassenpflug W, Obser T. Severe ADAMTS-13 deficiency in childhood［J］. Semin Hematol, 2004, 41(1): 83-89.

［25］Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases［J］. Blood, 2005, 106(4): 1262-1267.

［26］Lawlor ER, Webb DW, Hill A, Wadsworth LD. Thrombotic thrombocytopenic purpura: a treatable cause of childhood encephalopathy［J］. J Pediatr, 1997, 130(2): 313-316.

［27］Tripathi SP, Deshpande AS, Khadse S, Kulkarni RJ. Case of TTP with cerebral infarct secondary to platelet transfusion［J］. Indian J Pediatr, 2011, 78(1): 109-111.

［28］Swisher KK, Terrell DR, Vesely SK, Kremer Hovinga JA, Lammle B, George JN. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura［J］. Transfusion, 2009, 49(5): 873-887.

［29］Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura［J］. Blood, 2011, 118(7): 1746-1753.

［30］Curtillet C, Poullin P, Doré E, Fossat C, Lefevre P, Michel G. Paediatric case report of an acquired autoimmune thrombotic thrombocytopenic purpura［J］. Archives de pédiatrie, 2006, 13(12): 1521-1524.

［31］Albaramki JH, Teo J, Alexander SI. Rituximab therapy in two children with autoimmune thrombotic thrombocytopenic purpura［J］. Pediatr Nephrol, 2009, 24(9):1749-1752.

［32］Jayabose S, Dunbar J, Nowicki TS, Tugal O, Ozkaynak MF, Sandoval C. Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child［J］. Pediatr Hematol Oncol, 2011, 28(2): 167-172.

［33］Harambat J, Lamireau D, Delmas Y, Ryman A, Llanas B, Brissaud O. Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: A pediatric report and literature review［J］. Pediatr Crit Care Med, 2011, 12(2): 90-93.

［34］McDonald V, Liesner R, Grainger J, Gattens M, Machin SJ, Scully M. Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays［J］. Blood Coagul Fibrinolysis, 2010, 21(3): 245-250.

［35］Caramazza D, Quintini G, Abbene I, Coco LL, Malato A, Di Trapani R, et al. Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura—haemolytic uraemic syndrome［J］. Blood Transfus, 2010, 8(3): 203-210.

［36］Moskowitz NP, Fligman I, Scimeca P, Weinblatt M. Transient TTP in childhood［J］. Pediatr Blood Cancer, 2009, 52(3): 424-426.

［37］Brunner HI, Freedman M, Silverman ED. Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood［J］. Arthritis Rheum, 1999, 42(11): 2346-2355.

［38］Thampi S, Salmi D, Imashuku S, Ducore J, Satake N. Thrombotic thrombocytopenic purpura in a child with systemic lupus erythematosus［J］. J Pediatr Hematol Oncol, 2011, 33(3): 221-223.

［39］Yuen LK, Lai WM, Tong PC, Poon WT, Tse KC, Chiu MC. Recurrent thrombotic thrombocytopenic purpura in a young boy with systemic lupus erythematosus［J］. J Clin Rheumatol, 2007, 13(4): 224-228.

［40］Meyer R, Bussel JB. Consider thrombotic microangiopathy in pediatric and hematopoietic stem cell transplant patients［J］. Oncology (Williston Park), 2011, 25(10): 920-924.

［41］Plews DE, Turner ML, Wallace WHB. Plasma exchange as successful treatment of thrombotic thrombocytopenic purpura post autologous bone marrow transplant in a child［J］. Bone Marrow Transplant, 2000, 25(6): 679-680.

［42］Lee CH, Chen CL, Lin CC, Yang CH, Cheng YF, Wang MC, et al. Plasma exchange therapy for thrombotic thrombocytopenic purpura in pediatric patients with liver transplantation［J］. Transplant Proc, 2008, 40(8): 2554-2556.

［43］Nishi H, Hanafusa N, Kondo Y, Nangaku M, Sugawara Y, Makuuchi M, et al. Clinical outcome of thrombotic microangiopathy after living-donor liver transplantation treated with plasma exchange therapy［J］. Clin J Am Soc Nephrol, 2006, 1(4): 811-819.

［44］Sawant RB, Rajadhyaksha SB. Plasma exchange for thrombotic thrombocytopenic purpura following hematopoietic stem cell transplantation［J］. J Assoc Physicians India, 2005, 53: 981-983.

［45］Marr H, McDonald EJ, Merriman E, Smith M, Mangos H, Stoddart C, et al. Successful treatment of transplant-associated microangiopathy with rituximab［J］. NZ Med J, 2009, 122(1292): 72-74.

［46］Schiller O, Ash S, Schonfeld T, Kadmon G, Nahum E, Yacobovich J, et al. Postoperative thrombotic thrombocytopenic purpura in an infant: case report and literature review［J］. J Pediatr Surg, 2011, 46(4): 764-766.

［47］Naqvi TA, Baumann MA, Chang JC. Post-operative thrombotic thrombocytopenic purpura: a review［J］. Int J Clin Pract, 2004, 58(2):169-172.

［48］Majjiga VS, Tripathy AK, Viswanathan K, Shukla M. Thrombotic thrombocytopenic purpura and multiorgan system failure in a child with sickle cell-hemoglobin C disease［J］. Clin Pediatr (Phila), 2010, 49(10): 992-996.

［49］Chinowsky MS. Thrombotic thrombocytopenic purpura associated with sickle cell-hemoglobin C disease［J］. South Med J, 1994, 87(11): 1168-1171.

［50］Akbayram S, Dogan M, Peker E, Akgun C, Oner AF, Caksen H. Thrombotic thrombocytopenic purpura in a case of brucellosis［J］. Clin Appl Thromb Hemost, 2011, 17(3): 245-247.

［51］Kiki I, Gundogdu M, Albayrak B, Bilgi-Y. Thrombotic thrombocytopenicpurpura associated with Brucella infection［J］. Am J Med Sci, 2008, 335(3): 230-232.

［52］Erdem F, Kiki I, Gundo-du M, Kaya H. Thrombotic thrombocytopenic purpura in a patient with Brucella infection is highly responsive to combined plasma infusion and antimicrobial therapy［J］. Med Princ Pract, 2007, 16(4): 324-326.

［53］Koyfman A, Brém E, Chiang VW. Thrombotic thrombocytopenic purpura［J］. Pediatr Emerg Care, 2011, 27(11):1085-1088.